The mechanism that underpins this ‘substrate reduction’ action of ALs currently remains unclear, but in view of the high degree of synergy when combined with the substrate reduction therapy drug miglustat, it may not be a major contributor to AL’s therapeutic effect in NPC1 disease. This evidence concerns the gene SOD1 and Niemann-Pick disease, type C1.